Comprehensive Metabolic Panel (CMP) Testing Market Report 2026

The comprehensive metabolic panel (cmp) testing market size has grown strongly in recent years. It will grow from $18.34 billion in 2025 to $19.94 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, expansion of diagnostic laboratory networks, rising use of blood chemistry testing, improved access to routine health screening, growing awareness of preventive diagnostics.

The comprehensive metabolic panel (cmp) testing market size is expected to see strong growth in the next few years. It will grow to $28.57 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic solutions, expansion of decentralized testing models, rising adoption of integrated lab automation, growing focus on population health screening, increasing investments in diagnostic infrastructure. Major trends in the forecast period include increasing adoption of automated clinical chemistry analyzers, rising demand for routine metabolic screening, growing integration of laboratory information systems, expansion of point-of-care cmp testing, enhanced focus on early disease detection.

The rising prevalence of cardiovascular diseases and diabetes is expected to drive the growth of the comprehensive metabolic panel testing market in the coming years. Cardiovascular diseases affect the heart and blood vessels and are commonly associated with atherosclerosis, which involves the buildup of fatty deposits within the arteries. Diabetes is a metabolic disorder that occurs when blood glucose levels become abnormally high. Comprehensive metabolic panel blood tests are widely used to measure glucose levels and assess metabolic health. As the number of individuals affected by diabetes and cardiovascular diseases continues to increase, the demand for diagnostic tools such as CMP blood tests to support early detection, diagnosis, and monitoring is also rising, thereby supporting market growth. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease caused 919,032 deaths in 2023, accounting for approximately one in every three deaths. Coronary heart disease remained the most common form of heart disease, and notably, around one in six cardiovascular-related deaths occurred among adults under the age of 65. Therefore, the increasing burden of cardiovascular diseases and diabetes is contributing to the growth of the comprehensive metabolic panel testing market.

Major companies operating in the comprehensive metabolic panel testing market are increasingly focused on developing advanced diagnostic solutions such as integrated clinical chemistry and immunoassay analyzers to deliver faster, more efficient, and streamlined CMP testing workflows. Integrated clinical chemistry and immunoassay analyzers are unified systems capable of performing both chemistry and immunoassay tests on a single platform, allowing laboratories to reduce manual handling, improve turnaround times, and consolidate CMP and related testing panels. For instance, in July 2023, Siemens Healthineers AG, a Germany-based medical technology company, introduced the Atellica CI Analyzer, an integrated clinical chemistry and immunoassay system designed for laboratories requiring compact and high-quality CMP testing solutions. The Atellica CI Analyzer is a modular, random-access platform that combines chemistry and immunoassay testing within a single footprint, supports an extensive and growing assay menu, and incorporates digitized workflows and advanced reporting features to enhance turnaround times and sample traceability. It also includes automated sample management, priority testing capabilities, built-in diagnostics, and IT connectivity for LIS and HIS integration, enabling laboratories to consolidate CMP testing and related panels on one system while reducing hands-on time and accelerating clinical decision-making.

In March 2023, Fluxergy, a US-based medical diagnostics company, acquired selected staff, assets, and licensed electrochemical biosensing technologies from InnaMed Inc. for an undisclosed amount. Through this acquisition, Fluxergy expanded its detection capabilities to include clinical chemistry and small-molecule testing across human healthcare as well as equine and small animal veterinary applications. InnaMed Inc. is a US-based decentralized blood testing company that specializes in electrochemical biosensor technology.

Major companies operating in the comprehensive metabolic panel (cmp) testing market are Abbott Laboratories Inc., Siemens Healthineers AG, Mayo Clinic, Laboratory Corporation of America Holdings, Mercy, Mount Sinai Health System, Quest Diagnostics Incorporated, Sonic Healthcare Limited, Hologic Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Werfen SA, DiaSorin S.p.A., Randox Laboratories Ltd., ARUP Laboratories Inc., Invitae Corporation, Abaxis Inc., Metropolis Healthcare Limited, Clinical Reference Laboratory (CRL), Centogene AG, Spectra Laboratories, Unipath Systems Ltd., Scion Lab Services LLC, Weldon Biotech Pvt Ltd., Corona Pathology,Ulta Lab Tests LLC, Any Lab Test Now, Applied InGENuity Diagnostics LLC, Walk-In Lab LLC.

North America was the largest region in the comprehensive metabolic panel (CMP) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the comprehensive metabolic panel (cmp) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the comprehensive metabolic panel (cmp) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the comprehensive metabolic panel testing market by increasing costs of imported analyzers, reagents, calibration materials, and electronic components used in laboratory and point-of-care testing systems. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to reliance on imported diagnostic equipment, while Asia-Pacific faces pricing pressure on reagent supply chains. These tariffs are raising operational costs and impacting test affordability. However, they are also encouraging local production of diagnostic reagents, regional manufacturing of analyzers, and supply chain diversification to strengthen long-term testing accessibility.

The comprehensive metabolic panel (cmp) testing market research report is one of a series of new reports that provides comprehensive metabolic panel (cmp) testing market statistics, including comprehensive metabolic panel (cmp) testing industry global market size, regional shares, competitors with a comprehensive metabolic panel (cmp) testing market share, detailed comprehensive metabolic panel (cmp) testing market segments, market trends and opportunities, and any further data you may need to thrive in the comprehensive metabolic panel (cmp) testing industry. This comprehensive metabolic panel (cmp) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A comprehensive metabolic panel (CMP) test is a blood test that measures 14 different parameters to provide important information about the body’s chemical balance and metabolic function. It is commonly used to evaluate nutritional status, assess liver and kidney function, and support diagnosis, screening, and ongoing monitoring of various health conditions.

The primary disease areas associated with comprehensive metabolic panel testing include kidney disease, liver disease, diabetes, and others. Kidney disease refers to a condition in which the kidneys are damaged and unable to perform essential functions such as filtering waste from the blood. The different test types included in CMP testing cover proteins, electrolytes, kidney function tests, liver function tests, and glucose, and these tests are performed in laboratory settings as well as at the point of care.

The comprehensive metabolic panel (CMP) testing market includes revenues earned by entities by providing glucose tests, sodium tests, and albumin tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.